Searchable abstracts of presentations at key conferences in endocrinology

ea0032jp1 | Enhancing radioiodine uptake in thyroid cancer | ECE2013

Enhancing radioiodine uptake in thyroid cancer

Smith V E

Ablative radioiodine therapy is critical to the treatment of differentiated thyroid cancers and their metastases, and relies on the innate ability of thyroid cells to uptake iodide via the sodium iodide symporter (NIS). As tumours with reduced avidity for radioiodine have a poorer prognosis,it is critical to identify ways to induce NIS activity and hence radioiodine uptake.Pituitary tumor transforming gene (PTTG) and its interacting partner, PTTG-binding...

ea0024oc4.4 | Oral Communications 4 (Brief Communications) | BSPED2010

Support for insulin injections in schools – a survey

Senniappan S , Bohara K , Aravamudhan A , Wade C , Doyle P , Phillips V , Smith C

Introduction: One in 700 children of school age have diabetes. Children spend on average a quarter of their waking lives in school. It is important that children receive adequate support and supervision in school for the effective management of diabetes.Aim: To evaluate the support given by the schools for lunch time insulin injections, from the perspective of parents of children with diabetes.Methods: Questionnaire completed by di...

ea0019p174 | Endocrine tumours and neoplasia | SFEBES2009

PBF-mediated alteration of sodium iodide symporter localisation and activity in differentiated thyroid cancer

Smith V , Read M , Watkins R , Turnell A , James S , Eggo M , Boelaert K , Franklyn J , McCabe C

Radioiodine ablation of differentiated thyroid cancers and their metastases utilises the ability of the thyroid to accumulate iodide. However, most differentiated thyroid tumours exhibit reduced iodide uptake, with the mechanisms underlying this remaining poorly understood. Pituitary tumor transforming gene (PTTG) binding factor (PBF) is a proto-oncogene over-expressed in thyroid tumours, which we have shown to repress sodium iodide symporter (NIS) mRNA expression and inhibit ...

ea0019p371 | Thyroid | SFEBES2009

Enlargement of the thyroid gland in a heterozygous PBF knock-in transgenic mouse model

Read M , Fong J , Lewy G , Smith V , Turnell A , Watkins R , Seed R , Stewart S , Warfield A , Leadbeater W , Kim D , Watkinson J , Franklyn J , Boelaert K , McCabe C

PTTG binding factor (PBF) is a poorly characterised 22 kDa protein that is implicated in the aetiology of pituitary and thyroid tumours. Our recent investigations have attempted to discern the function of PBF in vitro. In particular, we reported that PBF can inhibit the activity of the sodium iodide symporter (NIS), which is responsible for iodide uptake into thyroid cells. However, little is known about the precise role of PBF in vivo. We have now generated a mu...

ea0029p1783 | Thyroid cancer | ICEECE2012

Regulation of hPTTG expression and phosphorylation: autocrine interactions with growth factors in thyroid cells

Lewy G. , Ryan G. , Read M. , Fong J. , Seed R. , Sharma N. , Smith V. , Kwan P. , Stewart S. , Warfield A. , Melmed S. , Eggo M. , Franklyn J. , McCabe C. , Boelaert K.

Introduction: The human Pituitary Tumor Transforming Gene (hPTTG) is a phosphorylated proto-oncogene induced in multiple tumour types. hPTTG phosphorylation is mediated by cyclin-dependent kinase 2 (CDC2) and expression is regulated by specificity protein 1 (SP1). In thyroid cancer, hPTTG induces genetic instability and propagates growth through induction of growth factors (GFs).Methods: The interplay between hPTTG phosphorylation, SP1 regulation and GF ...